Association of Breg and Treg With the Clinical Effects of Infliximab in the Treatment of Patients With Crohn's Disease
Condition: Crohn Disease Intervention: Drug: Infliximab Sponsor: Second Affiliated Hospital of Wenzhou Medical University Completed
In conclusion, reduced DJ-1 expression promotes inflammation and IEC apoptosis via p53 in colitis, suggesting that the modulation of DJ-1 expression may be a potential therapeutic strategy for managing colitis.
The long-hyped redefinition of healthcare through wearable tech has been … well, long hyped. Early projects, such as Apple HealthKit and Fitbit, were undoubtably important in redefining ‘the possible’ but they haven’t yet achieved transformative application. Much has been written on why the philosophy that has driven the astonishing success of consumer technology doesn ’t translate to healthcare and when we look at the state of innovation in 2020, many of these structural issues remain. As Emily Cerciello, Associate Director, Digital Health and Engagement at the Crohn's...
(The Mount Sinai Hospital / Mount Sinai School of Medicine) In a series of four studies published today in Gastroenterology, a journal of the American Gastroenterological Association, Mount Sinai inflammatory bowel disease (IBD) researchers, describe the identification of predictive tools and a new understanding of environmental factors that trigger IBD.
(Scripps Research Institute) The US Food and Drug Administration has approved ozanimod, an immune-modulating therapy invented at Scripps Research, for the treatment of adults with relapsing forms of multiple sclerosis. The drug is also in advanced clinical development for adults and children with moderate-to-severe ulcerative colitis and Crohn's disease.
Condition: Crohn Disease in Remission Interventions: Other: Faecal calprotectin (FC); Other: quantitative Faecal Immunochemical Testing (qFIT); Other: Serum and faecal zinc Sponsor: NHS Greater Glasgow and Clyde Not yet recruiting
This study extended the clinical utility of a previously validated clinical decision support tool for predicting treatment effectiveness of vedolizumab in Crohn's disease.Alimentary Pharmacology &Therapeutics
Conclusion: Newly diagnosed pediatric patients with IBD show significantly less diverse microbiota and microbial composition compared with healthy siblings and healthy controls.
Exclusive enteral nutrition (EEN) is effective in inducing remission in paediatric Crohn Disease (CD) and has been shown to reduce inflammation and improve outcomes in adult CD patients when used before resectional surgery. This retrospective study demonstrates that preoperative EEN is achievable in paediatric CD patients undergoing right hemicolectomy and is associated with positive peri-operative outcomes. Seventeen patients (8 who received preoperative EEN and 9 who did not) were included in the study. Six of 8 (75.0%) managed EEN orally; 1 via nasogastric tube and another via a previously sited gastrostomy. Use of preo...
In patients with inflammatory bowel diseases (IBD), symptoms do not always associate with the severity of endoscopic inflammation and can persist after mucosal healing. We investigated whether symptoms in patients with successfully treated IBD are related to composition of the intestinal microbiome.
Inflammatory bowel disease (IBD), which comprises ulcerative colitis and Crohn's disease, is an immune-mediated, chronic-relapsing, disabling disorder which is associated with increased mortality and poor patients' quality of life. Patients with IBD are at increased risk of infections for many reasons. In fact, IBD often requires a lifelong immunosuppressive and/or biologic therapy, both commonly associated with respiratory and opportunistic infections, but also gastrointestinal, urinary tract infections, and sepsis. Moreover, impaired spleen function has been found in a considerable proportion of IBD patients, further inc...